| ［1］ 朱小鹏, 唐昃. NP方案联合同步放疗治疗局部晚期非小细胞肺癌的疗效观察［J］. 临床肺科杂志, 2013, 18(1): 164-165. ［2］ NSCLC MetaAnalyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced nonsmallcell lung cancer: asystematic review and metaanalysis of individual patient data from 16 randomized controlled trials［J］. J Clin Oncol, 2008, 26(28): 4617-4625. ［3］ AlSaleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced nonsmallcell lung cancer: metaanalysis of randomized controlled trials, with histology subgroup analysis［J］. Curr Oncol, 2012, 19(1): e9-e15. ［4］ Joerger M, Omlin A, Cerny T, et al. The role of pemetrexed in advanced non smallcell lung cancer: special focus on pharmacology and mechanism of action［J］. Curr Drug Targets, 2010, 11(1): 37-47. ［5］ 王治宽, 胡毅, 赵宏, 等. 晚期肺腺癌胸苷酸合成酶和培美曲塞疗效分析［J］. 南方医科大学学报, 2010, 30(5): 978-980. ［6］ Mir O, BoudouRouquette P, Giroux J, et al. Pemetrexed, oxaliplatin and bevacizumab as firstline treatment in patients with stage Ⅳ nonsmall cell lung cancer［J］. Lung Cancer, 2012, 77(1): 104-109. ［7］ Misset JL, Gamelin E, Campone M, et al. Phase Ⅰ and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors［J］. Ann Oncol, 2004, 15(7): 1123-1129. ［8］ 田述梅. 培美曲塞联合奥沙利铂或顺铂一线治疗晚期肺腺癌的临床研究［J］. 现代医药卫生, 2012, 28(17): 2570-2572. ［9］ Shi SB, Hu RH, Qi JL, et al. Treatment of stage Ⅲb/Ⅳ nonsmall cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as secondline treatment［J］. Med Oncol, 2013, 30(2): 550. |
